Introduction
Parkinson's disease (PD) is a very common movement dis order characterized by dopaminergic neuronal loss. The major ity of PD cases are sporadic; however, the discovery of genes linked to rare familial forms of this disease has provided important insight into the molecular mechanisms of disease pathogenesis (Moore et al., 2005; Hardy et al., 2006) . In 2000, we and others found that dysfunction of an E3 ubiquitin ligase (Imai et al., 2000; Shimura et al., 2000; Zhang et al., 2000) termed Parkin causes autosomal recessive juvenile Parkinsonism (Kitada et al., 1998) . Since then, a multitude of papers have been published, but the mechanism by which dysfunction of Parkin causes autosomal recessive juvenile Parkinsonism has largely remained obscure, and claims of pathogenicity remain controversial (Lim, 2007; Matsuda and Tanaka, 2010) . In addition, PINK1 (PTEN-induced putative kinase 1) was identified in 2004 as the gene responsible for another form of earlyonset PD (Valente et al., 2004) . PINK1 functions in mitochondrial maintenance, suggesting that mito chondrial integrity is another key factor in disease patho genesis (Dodson and Guo, 2007; Schapira, 2008) . Intriguingly, genetic studies using Drosophila melanogaster revealed that PINK1 and Parkin function in the same pathway, with PINK1 functioning upstream of Parkin (Clark et al., 2006; Park et al., 2006; Yang et al., 2006) . Little is known about how PINK1 P arkinson's disease (PD) is a prevalent neuro degenerative disorder. Recent identification of genes linked to familial forms of PD such as Parkin and PINK1 (PTEN-induced putative kinase 1) has revealed that ubiquitylation and mitochondrial integrity are key factors in disease pathogenesis. However, the exact mechanism underlying the functional interplay between Parkin catalyzed ubiquitylation and PINK1regulated mitochon drial quality control remains an enigma. In this study, we show that PINK1 is rapidly and constitutively degraded under steadystate conditions in a mitochondrial mem brane potential-dependent manner and that a loss in mitochondrial membrane potential stabilizes PINK1 mitochondrial accumulation. Furthermore, PINK1 recruits Parkin from the cytoplasm to mitochondria with low mem brane potential to initiate the autophagic degradation of damaged mitochondria. Interestingly, the ubiquitin ligase activity of Parkin is repressed in the cytoplasm under steadystate conditions; however, PINK1dependent mito chondrial localization liberates the latent enzymatic activ ity of Parkin. Some pathogenic mutations of PINK1 and Parkin interfere with the aforementioned events, suggest ing an etiological importance. These results provide crucial insight into the pathogenic mechanisms of PD. regulates Parkin, and our knowledge, especially in mammals, of their relationship is limited. In this study, we describe the mechanism underlying the functional interplay between ubiq uitylation catalyzed by Parkin and mitochondrial quality con trol regulated by PINK1.
Results and discussion
Parkin localizes to and ubiquitylates mitochondria with low membrane potential
We initially sought to study the subcellular localization and E3 activity of Parkin using HeLa cells, which reportedly lack a functional Parkin gene (Denison et al., 2003) . In support of that study, we found that endogenous Parkin was barely detectable in HeLa cells even when PRK8, the bestcharacterized specific antiParkin antibody (Pawlyk et al., 2003) , was used (Fig. S1 A) . Consequently, HAParkin was exogenously intro duced into HeLa cells. Under steadystate conditions, HA Parkin was diffusely localized throughout the cytosol and did not overlap with mitochondria, whereas Parkin was rapidly recruited to the mitochondria when HeLa cells were treated with the mitochondrial uncoupler CCCP (carbonyl cyanide mchlorophenylhydrazone; Fig. 1 A) , as reported by Narendra et al. (2008) . Next we tried to confirm the redistribution of Parkin from the cytoplasm to the mitochondria using a bio chemical approach. In fractionation experiments, detection of Parkin in the mitochondriarich fraction was faint, probably because Parkin was weakly associated with the mitochondria and thus unstable during fractionation. Inclusion of the cross linker DSP (dithiobis[succinimidyl propionate]) significantly strengthened the signal and further confirmed redistribution of exogenous ( Fig. 1 B, left) and endogenous ( Fig. 1 B, right) Parkin from the cytoplasm to a mitochondriaenriched frac tion. (Note that endogenous Parkin in SHSY5Y cells is detect able as a doublet, which is consistent with a previous study [Pawlyk et al., 2003] .) To more convincingly demonstrate that Parkin is selectively recruited to depolarized mitochondria, we used MitoTracker red CMXRos, which accumulates in mitochondria with an intact membrane potential. Incomplete treatment with CCCP can generate cells in which healthy and damaged mitochondria coexist. Under these conditions, signals of Parkin and MitoTracker were mutually exclusive, and Parkin selectively localized on mitochondria with lower MitoTracker red staining (Fig. 1 D) , indicating that Parkin was selectively tar geted to mitochondria whose membrane potential had been lost.
Subsequently, we performed immunofluorescence stain ing using an antiubiquitin antibody. Under normal conditions, the ubiquitin signal was spread throughout the cell. In contrast, when cells were treated with CCCP, the ubiquitin signal was concentrated in the mitochondria (Fig. 2, A and B) . Mitochondrial ubiquitylation was only observed in Parkin expressing cells (Fig. 2 A and Fig. S1 B) and disappeared when Parkin mutants deficient in E3 activity (T415N and G430D) were introduced (Fig. 2 A) . Triple staining using mitochondriatargeting GFP (MtGFP), antiParkin, and anti ubiquitin antibodies further confirmed the colocalization of Parkin, ubiquitin, and mitochondria after CCCP treatment (Fig. 2 C) . Staining with single antibodies or MtGFP alone indicated that the aforementioned merged data were not de rived from channel cross talk (Fig. S1, C and D ). These results demonstrate that Parkin ubiquitylates mitochondria in re sponse to a reduction in mitochondrial membrane potential.
Disease-relevant mutations of Parkin impair mitochondrial localization
To confirm that translocation of Parkin to depolarized mito chondria is etiologically important, we selected nine patho genic mutations and examined their subcellular localization ( Fig. 1 C) . In vitro experiments have previously shown that two of the mutations (T415N and G430D) in the RING2 domain abolish E3 activity of Parkin, whereas E3 activity is unaffected by the other mutations (Hampe et al., 2006; Matsuda et al., 2006) . These mutants were serially introduced into HeLa cells, fol lowed by CCCP treatment, and their subcellular localization was examined. Parkin with the D280N or G328E mutation in RING1 or the IBR (in between RING) domain, respectively, was recruited to the mitochondria in a manner similar to wild type Parkin (Fig. 1, E and F) . In contrast, the other pathogenic mutations altered to some degree the mitochondrial localiza tion of Parkin; in particular, the K161N, K211N, and T240R mutations, which lie in or near the RING0 domain in the linker region (Hristova et al., 2009) , severely compromised the mito chondrial localization of Parkin (Fig. 1, E and F) . The afore mentioned results suggest that mitochondrial localization of Parkin is pathologically significant and that the RING0 domain is important for the translocation of Parkin to the damaged mitochondria.
Parkin exerts E3 activity only when the mitochondrial membrane potential decreases
As shown in Fig. 2 C and Fig. S1 B, mitochondrial ubiqui tylation was dependent on Parkin translocation to the mito chondria. Thus, we tried to determine whether the subcellular localization of Parkin modulates its E3 activity. To address this issue, we monitored the E3 activity of Parkin using an artificial substrate fused to Parkin. In vitro experiments have shown that Parkin can ubiquitylate an Nterminally fused lysinerich protein as a pseudosubstrate (Matsuda et al., 2006) . Similar ubiquitylation of pseudosubstrates even in the cytoplasm under normal conditions in vivo would be evidence that the E3 activity is constitutive; otherwise, E3 activity of Parkin is dependent on mitochondrial retrieval. A GFP tag is lysine rich and thus a good candidate for an in vivo pseudo substrate, whereas an HA tag possesses no lysine residues and thus cannot function as a pseudosubstrate. GFP and HA Parkin expressed in HeLa cells treated with CCCP were both recruited to damaged mitochondria (Figs. 1 A and 2 D) , but interestingly, a higher molecular mass population of only GFP Parkin was observed (Fig. 2 F) . Immunoprecipitation experi ments demonstrated that GFPParkin was indeed ubiquitylated (Fig. 2 E) . This was not based on autoubiquitylation of Parkin itself because mitochondriaassociated HAParkin did not undergo ubiquitylation after CCCP treatment ( Fig. 2 F and not depicted). Moreover, ubiquitylation of GFPParkin was absent in the T415N and G430D mutants, which lack E3 activities, suggesting that ubiquitylation of GFPParkin is not derived from other E3s (Fig. 2 G) . The K161N and K211N mutants that impaired mitochondrial localization also inhibited ubiqui tylation of GFPParkin (Fig. 2 G) . Collectively, the aforemen tioned results indicate that Parkin ubiquitylates fused GFP only when it is retrieved to the mitochondria, suggesting that the latent E3 activity of Parkin is dependent on decreased mito chondrial membrane potential.
PINK1 localization is stabilized by damaged mitochondria
Recessive mutations in the human PINK1 gene are also the cause of autosomal recessive earlyonset PD (Valente et al., 2004) . We next examined whether the subcellular localization of PINK1 was affected by mitochondrial membrane potential. As reported previously (Valente et al., 2004; Beilina et al., 2005; Takatori et al., 2008) , Nterminal Myc-or Nterminal Flag-tagged PINK1 clearly localized to the mitochondria, whereas Cterminal Flagor Cterminal V5-tagged PINK1 mainly localized to the cyto plasm ( Fig. 3 A and not depicted) . Exogenous nontagged PINK1 also localized to the cytoplasm under steadystate conditions (Fig. 3 B) , suggesting that mitochondrial localization of PINK1 is an artifact of the Nterminal epitope. More importantly, similar to Parkin, untagged PINK1 and Cterminal Flag-or Cterminal V5-tagged PINK1 localized to the mitochondria after CCCP treatment (Fig. 3, A and B; and not depicted). These results sug gest that the subcellular localization of PINK1 is also regulated by the mitochondrial membrane potential.
We next sought to determine the subcellular localization of endogenous PINK1. Immunocytochemical experiments showed, as reported previously (Zhou et al., 2008) , that the endogenous PINK1 signal was barely detectable in HeLa cells under steadystate conditions. However, a decrease in mitochon drial membrane potential resulted in a mitochondriaassociated PINK1 signal (Fig. 3, C and D) . We found that CCCP treat ment promoted the gradual accumulation of endogenous PINK1 in immunoblots as well (Fig. 3 E) and the presence of endogenous PINK1 in a mitochondriaenriched fraction (Fig. 3 F) . More importantly, when CCCP was washed out, the accumu lated endogenous PINK1 rapidly disappeared (within 30 min) both in the presence and absence of cycloheximide (Fig. 3 G  and not depicted) . Moreover, the Nterminal 34 aa of PINK1 sufficiently recruited GFP to the mitochondria even in the ab sence of CCCP (Fig. 3 H) . These results support the hypothesis in which PINK1 is constantly transported to the mitochondria but is rapidly degraded in a membrane potential-dependent manner. We speculate that PINK1 is stabilized by a decrease in mitochondrial membrane potential and, as a result, accumu lates in depolarized mitochondria.
PINK1 normally exists as either a long (60 kD) or a short (50 kD) protein. Because the canonical mitochondria targeting signal (matrixtargeting signal) is cleaved after import into the mitochondria, the long form has been designated as the precursor and the short form as the mature PINK1 (Beilina et al., 2005; Silvestri et al., 2005) . The short (processed) form of PINK1 was clearly detected when untagged PINK1 was over expressed (Fig. 3 E, sixth lane) ; however, this form of endog enous PINK1 was rarely detectable after CCCP treatment (Fig. 3 E, the first through the fifth lanes). Our subcellular local ization study of endogenous PINK1 after CCCP treatment showed that the long form was recovered in the mitochondrial fraction (Fig. 3 F) , suggesting that it is not the preimport pre cursor form. Moreover, by monitoring the degradation process of PINK1 after recovery of membrane potential, we realized that the short form of PINK1 transiently appeared soon after CCCP was washed out and then later disappeared (Fig. 3 G) , suggesting that the processed form of PINK1 is an intermedi ate in membrane potential-dependent degradation. In conclu sion, these results imply that PINK1 cleavage dose not reflect a canonical maturation process accompanying mitochondrial import as initially thought.
PINK1 retrieves Parkin from the cytoplasm to the mitochondria
Because previous studies revealed that PINK1 functions upstream of Parkin (Clark et al., 2006; Park et al., 2006; Yang et al., 2006; Exner et al., 2007) , we next examined the potential role of PINK1 in the mitochondrial recruitment of Parkin. To obtain clearcut conclusions, we set up our experimental system using mouse embryonic fibroblasts (MEFs) derived from control ) mouse (Gautier et al., 2008) . Endogenous Parkin is undetectable in MEFs ( Fig. S1 A) ; consequently, HA or GFPParkin was introduced into these cells by retroviral transfection (Kitamura et al., 2003) . In control MEFs (PINK1 +/+ ), Parkin was selectively recruited to the mito chondria after CCCP treatment (Fig. 4 A) and subsequently resulted in the disappearance of the mitochondria (Fig. 4 , D and E). This mitochondrial clearance was considerably impeded by Atg7 (essential gene for autophagy) knockout ( Fig. S2 ; Komatsu et al., 2005) , suggesting that Parkin degrades mitochondria by selective autophagy as reported previously (Narendra et al., 2008) . In sharp contrast, Parkin was not is specifically linked to a decrease in membrane potential, (c) under steadystate conditions, the E3 activity of Parkin is repressed in the cytoplasm but is liberated by PINK1dependent mitochondrial localization, and (d) the aforementioned phe nomena are presumably etiologically important in part because they were impeded for the most part by diseaselinked muta tions of PINK1 or Parkin. We believe that these results provide solid insight into the molecular mechanisms of PD pathogenesis not only for familial forms caused by Parkin and PINK1 muta tions but also major sporadic forms of PD.
Materials and methods
Cell culture and transfection MEFs derived from embryonic day 12.5 embryos of PINK1 knockout mice (provided by J. Shen, Harvard Medical School, Boston, MA) were mechanically dispersed by repeated passage through a P1000 pipette tip and plated with MEF media containing DME, 10% FCS, -mercaptoethanol (SigmaAldrich), 1× nonessential amino acids, and 1 mM l-glutamine. Various stable transformants of MEFs were established by infecting MEFs with recombinant retroviruses. HA-Parkin, GFP-Parkin, PINK1 (provided by Y. Nakamura, T. Iwatsubo, and S. Takatori, University of Tokyo, Bunkyo-ku, Tokyo, Japan), or various PINK1 mutants were cloned into a pMXs-puro vector. Retrovirus packaging cells, PLAT-E (provided by T. Kitamura, University of Tokyo; Kitamura et al., 2003) , were transfected with the aforementioned vectors and were cultured at 37°C for 24 h. After changing the medium, cells were further incubated at 37°C for 24 h, and the viral supernatant was collected and used for infection. MEFs were plated on 35-mm dishes at 24 h before infection, and the medium was replaced with the aforementioned undiluted viral supernatant with 8 µg/ml polybrene (Sigma-Aldrich). 2 d later, transformants were selected by the medium containing 10 µg/ml puromycin.
Cell fractionation and immunoprecipitation
To depolarize the mitochondria, HeLa and SH-SY5Y cells were treated with 10 µM CCCP, and MEFs were treated with 30 µM CCCP. For fractionation experiments, HeLa and SH-SY5Y cells were treated with CCCP for 1-5 h and subsequently treated with 1 mM DSP (Thermo Fisher Scientific) in PBS for 1 h on ice, inactivated by 10 mM glycine in PBS three times, and suspended in chappell-perry buffer (0.15 M KCl, 20 mM Hepes-NaOH, pH 8.1, 5 mM MgCl 2 , and protease and phosphatase inhibitor [Roche] ). Cells were disrupted by five passages through a 25-gauge needle (with 1-ml syringe), debris was removed by centrifugation at 1,000 g for 7 min, and the supernatant was subjected to 10,000 g for 10 min to separate the mitochondria-rich fraction from the cytosol-rich fraction. Immunoblotting and immunoprecipitation were performed by conventional methods. To detect the ubiquitylation of GFP-Parkin, the cell lysate of HeLa cells (10 µM CCCP for 1 h) or MEFs (30 µM CCCP for 3 h) was collected in the presence of 10 mM N-ethylmaleimide to protect ubiquitylated Parkin from deubiquitylation enzymes. To monitor the degradation of endogenous PINK1, HeLa cells were treated with 10 µM CCCP and 50 µg/ml cycloheximide as depicted in (Fig. 4 D and Fig. S2 A) . For immunofluorescence experiments, cells were fixed with 4% paraformaldehyde, permeabilized with 50 µg/ml digitonin, and stained with primary antibodies described in the next section and with the following secondary antibodies: mouse and/or rabbit Alexa Fluor 488, 568, and 647 (Invitrogen). N-terminal 34 aa of PINK1 were fused to GFP to stain mitochondria in the triple staining experiments. To monitor the mitochondrial membrane potential, MEFs were treated with 50 nM MitoTracker red CMXRos (Invitrogen) for 15 min, washed three times, and incubated for an additional 10 min before fixation, as reported previously (Narendra et al., 2008) . Cells were imaged using a laser-scanning microscope (LSM510 META; Carl Zeiss, Inc.) with a Plan-Apochromat 63× NA 1.4 oil differential interference contrast objective lens. Image contrast and brightness were adjusted in Photoshop (Adobe).
translocated to the mitochondria in PINK1 knockout (PINK1 / ) MEFs after CCCP treatment (Fig. 4, A and B) . Subsequent activation of Parkin and mitochondrial degradation were also completely impeded (Fig. 4, C-E) . To exclude the possible role of retroviral integration of Parkin in the aforementioned pheno type, we checked whether reintroduction of PINK1 rescued this phenotype. Untagged or Cterminal Flag-tagged PINK1 com plemented the mislocalization of Parkin in PINK1 / MEFs (Fig. 5, B and C; and not depicted), confirming that the afore mentioned defects were caused by the loss of PINK1.
To examine whether pathogenic mutations of PINK1 affect its mitochondrial localization, we expressed PINK1 mutants harboring the missense mutations E240K and G309D, or a CAA nucleotide insertion behind C1602 (referred to here after as 1602insert) in PINK1 / MEFs. Similar to wildtype PINK1, these PINK1 mutants colocalized with mitochondria after CCCP treatment (Fig. S3) . Next, GFPParkin was intro duced into these cells to examine whether pathogenic mutations of PINK1 affect the mitochondrial localization and activation of Parkin. The E240K and G309D mutants restored the mitochon drial localization and activation of Parkin as well as wildtype PINK1, whereas recruitment of Parkin to the mitochondria by the 1602insert mutant was abolished (Fig. 5, B-D) , suggesting that the pathology of this PINK1 mutation is mislocalization and consequent inactivation of Parkin. Finally, we investigated the role of various PINK1 domains (Fig. 5 A) in the mitochondrial recruitment of Parkin. PINK1 is composed of an atypical Nterminal mitochondrial localiza tion signal and transmembrane domain, a kinase domain in the middle, and a conserved Cterminal domain (Zhou et al., 2008) . Deletion of the Nterminal 91 aa abolished the mitochondrial localization of PINK1 (Zhou et al., 2008) . We also confirmed that the ∆N91 and ∆N155 mutants did not target to the mito chondria even after CCCP treatment (Fig. S3) . We also gener ated a mutant containing the triple K219A, D362A, and D384A mutations that abolish kinase activity (Beilina et al., 2005 ) and a Cterminal domain deletion mutant associated with PINK1 dysfunction (Sim et al., 2006; Yang et al., 2006) . The kinase dead and ∆C72 mutants of PINK1 colocalized with damaged mitochondria similar to wild type (Fig. S3) . When introduced into PINK1 / cells harboring GFPParkin, the mutants were unable to complement the mislocalization and inactivation of Parkin (Fig. 5, B-D) , even though the mutant PINK1 proteins were expressed (Fig. 5 D and Fig. S3 ). These results indicate that the kinase activity and mitochondrial targeting of PINK1 are essential for the mitochondrial recruitment of Parkin.
Conclusion
In summary, we have shown that (a) PINK1 is a Parkin recruitment factor that recruits Parkin from the cytoplasm to dam aged mitochondria in a membrane potential-dependent manner for mitochondrial degradation, (b) endogenous PINK1 is con stitutively degraded at the mitochondria, but its localization Online supplemental material Fig. S1 shows various control experiments for immunoblotting and immunocytochemistry. Fig. S2 shows that Parkin promoted degradation of depolarized mitochondria via autophagy. Fig. S3 shows the subcellular localization of pathogenic and deletion mutants of PINK1 after CCCP treatment. Online supplemental material is available at http://www.jcb .org/cgi/content/full/jcb.200910140/DC1.
